Change in peripheral blood lymphocyte count in dogs following adoptive immunotherapy using lymphokine-activated T killer cells combined with palliative tumor resection

Mie, Keiichiro; Shimada, Terumasa; Akiyoshi, Hideo; Hayashi, Akiyoshi; Ohashi, Fumihito

doi:10.1016/j.vetimm.2016.06.007

Cited by 14 publications

(13 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…T lymphocytes are important for anti-tumor immune responses. Therefore, enhancement of T lymphocytes may have utility in slowing, or halting, the progression of malignant tumors [61]. Adoptive cell transfer treatment involves the infusion of tumor-specific T lymphocytes into the circulatory system of cancer patients and has been extensively studied in human oncology.…”

Section: Lymphokine-activated Killer (Lak) Cell Therapymentioning

confidence: 99%

“…This form of immunotherapy is expected to trigger the cytotoxic activity of the administered lymphocytes against target tissues, and indirectly induce cell-mediated immunity by activation of T lymphocytes and natural killer cells [63]. In human medicine, LAK therapy has been applied for patients with tumors in combination with surgery to prevent postoperative tumor recurrence and metastasis by improving the postoperative immune responses suppressed by surgical stress [61]. Therefore, LAK cell transfer is not suitable as a monotherapy, but its application is promising as an adjuvant treatment [7].…”

Section: Lymphokine-activated Killer (Lak) Cell Therapymentioning

confidence: 99%

“…T lymphocytes were generated from autologous peripheral blood mononuclear cells by culture with recombinant human IL-2 and solid phase anti-canine CD3 antibodies. Therapy was administered intravenously at two to four-week intervals [61] and resulted in an increase of CD8 + T-cells and a decreased ratio of CD4+ to CD8+ T-cells [7]. Although promising results, the sample size was small, only three phenotypes were evaluated (CD3+, CD4+, and CD8+), and no clinical follow-up was performed [61].…”

Section: Lymphokine-activated Killer (Lak) Cell Therapymentioning

confidence: 99%

See 2 more Smart Citations

A Review of Immunotherapeutic Strategies in Canine Malignant Melanoma

Almela

Ansón

2019

Veterinary Sciences

View full text Add to dashboard Cite

In dogs, melanomas are relatively common tumors and the most common form of oral malignancy. Biological behavior is highly variable, usually aggressive, and frequently metastatic, with reported survival times of three months for oral or mucosal melanomas in advanced disease stages. Classical clinical management remains challenging; thus, novel and more efficacious treatment strategies are needed. Evidence-based medicine supports the role of the immune system to treat neoplastic diseases. Besides, immunotherapy offers the possibility of a precise medicinal approach to treat cancer. In recent years, multiple immunotherapeutic strategies have been developed, and are now recognized as a pillar of treatment. In addition, dogs represent a good model for translational medicine purposes. This review will cover the most relevant immunotherapeutic strategies for the treatment of canine malignant melanoma, divided among five different categories, namely, monoclonal antibodies, nonspecific immunotherapy activated by bacteria, vaccines, gene therapy, and lymphokine-activated killer cell therapy.

show abstract

Section: Lymphokine-activated Killer (Lak) Cell Therapymentioning

confidence: 99%

Section: Lymphokine-activated Killer (Lak) Cell Therapymentioning

confidence: 99%

Section: Lymphokine-activated Killer (Lak) Cell Therapymentioning

confidence: 99%

See 1 more Smart Citation

A Review of Immunotherapeutic Strategies in Canine Malignant Melanoma

Almela

Ansón

2019

Veterinary Sciences

View full text Add to dashboard Cite

show abstract

“…Several papers described LAK cells’ generation and anticancer activity against canine thyroid carcinoma and melanoma cell lines in vitro [ 97 – 99 ]. Recently, LAK cell therapy, in combination with surgery, was evaluated in vivo in 15 tumor-bearing dogs [ 100 ]. Patients received five rounds of LAK cell transfer with 2–4 weeks intervals.…”

Section: Lymphokine-activated Killer (Lak) Cells For Adoptive Cell Thmentioning

confidence: 99%

Adoptive cell transfer: new perspective treatment in veterinary oncology

et al. 2018

View full text Add to dashboard Cite

Cancer immunotherapy is recently considered the most promising treatment for human patients with advanced tumors and could be effectively combined with conventional therapies such as chemotherapy or radiotherapy. Patients with hematological malignancies and melanoma have benefited greatly from immunotherapies such as, adoptive cell transfer therapy, experiencing durable remissions and prolonged survival. In the face of increasing enthusiasm for immunotherapy, particularly for the administration of tumor-specific T lymphocytes, the question arises whether this method could be employed to improve treatment outcomes for canine patients. It is warranted to determine whether veterinary clinical trials could support comparative oncology research and thus facilitate the development of new cell-based therapies for humans. Herein, we discuss adoptive transfer of T lymphocytes and lymphokine-activated cells for application in veterinary oncology, in the context of human medicine achievements. Furthermore, we discuss potential benefits of using domestic dog as a model for immunotherapy and its advantages for translational medicine. We also focus on an emerging genome-editing technology as a useful tool to improve a T cells’ phenotype.

show abstract

“…In human medicine, lymphokine-activated killer (LAK) cell therapy is administered for improvement of the immune response and prevention of recurrence and metastasis after the cancer resection (Mie et al ., 2016).…”

Section: Introductionmentioning

confidence: 99%

Lymphokine-activated killer cell transplantation after anti-cancer treatment in two aged cats

et al. 2019

View full text Add to dashboard Cite

Immunotherapy improves both survival and remission rates after cancer surgery in humans, but its veterinary use has been limited. We determined the safety and feasibility of lymphokine-activated killer (LAK) cell transplantation in two aged cats that had undergone surgery for malignancy. Case 1 involved an 18-year-old male Japanese domestic cat. The cat exhibited appetite loss and poor physical activity after the surgical excision of oral squamous cell carcinoma followed by four sessions of radiotherapy, and the owner strongly requested immunotherapy for preventing further deterioration in the animal’s quality of life (QOL). We subsequently administered LAK cells three times during a 2-month period. Case 2 involved a 20-year-old female Japanese domestic cat who had undergone mammectomy after a diagnosis of breast adenocarcinoma. The owner strongly requested immunotherapy for QOL maintenance. We administered LAK cells four times over a period of 5 months. Autologous peripheral blood mononuclear cells (PBMCs) fractionated using density gradient centrifugation were cultured in the media containing a high concentration of interleukin-2 and supplemented with 2.5% fetal calf serum. The derived LAK cells were centrifuged, suspended in 10 ml of saline containing 1% of the subject’s own blood, and infused into the cephalic vein of the cats over 30 min. The composition ratios of CD3, CD4, CD8, and CD21 were evaluated by flow cytometry. Bacterial culture and endotoxin testing for a sample of LAK cells showed negative results in both the cases. The leukocyte and erythrocyte counts and the body temperature were assessed on days 7, 14, and 21 after the transfusion. No abnormal signs were observed in either case, which confirmed the safety of the procedure. QOL scores showed no significant changes after the treatment, and the body temperature remained steady throughout the treatment. The findings from these cases suggest that the transplantation of LAK cells derived from PBMCs may be safe and feasible for use in cats, regardless of their age.

show abstract

Change in peripheral blood lymphocyte count in dogs following adoptive immunotherapy using lymphokine-activated T killer cells combined with palliative tumor resection

Cited by 14 publications

References 37 publications

A Review of Immunotherapeutic Strategies in Canine Malignant Melanoma

A Review of Immunotherapeutic Strategies in Canine Malignant Melanoma

Adoptive cell transfer: new perspective treatment in veterinary oncology

Lymphokine-activated killer cell transplantation after anti-cancer treatment in two aged cats

Contact Info

Product

Resources

About